The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A prospective phase 2 single-arm study to evaluate the efficacy and safety of neoadjuvant pembrolizumab plus chemotherapy in patients with locally advanced esophageal squamous cell carcinoma (Keypoint-1).
 
Peiran Xu
No Relationships to Disclose
 
Polan Su
No Relationships to Disclose
 
Weiwei Wang
No Relationships to Disclose
 
Jia He
No Relationships to Disclose
 
Luo Zhao
No Relationships to Disclose
 
Weixun Zhou
No Relationships to Disclose
 
Robert Merritt
Consulting or Advisory Role - AstraZeneca
Speakers' Bureau - Intuitive Surgical
 
Li Li
No Relationships to Disclose
 
Kai He
Consulting or Advisory Role - AstraZeneca; BioNTech SE; Bristol-Myers Squibb; Iovance Biotherapeutics; Lyell Immunopharma; Mirati Therapeutics; Obsidian Therapeutics; Perthera
Research Funding - Abbvie (Inst); Adaptimmune (Inst); Amgen (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Iovance Biotherapeutics (Inst); Mirati Therapeutics (Inst); Oncoc4 (Inst)